Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Lui

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
CNS Drugs|September 13, 2022
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic ReviewNiloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, et al.
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
Psychiatry Research|April 28, 2020
Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disordersJoshua D Rosenblat, Rodrigo B Mansur, Elisa Brietzke, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 8, 2020
Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatmentAshley N Siegel, Nelson Rodrigues, Flora Nasri, et al.
Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.
Journal of Affective Disorders|July 16, 2020
The utility of smartphone-based, ecological momentary assessment for depressive symptomsSamantha J Yim, Leanna M W Lui, Yena Lee, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
Infectious Diseases (London, England)|March 14, 2022
Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for researchFelicia Ceban, Alexia Leber, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research|June 18, 2023
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic reviewDaniel H Cooper, Ranuk Ramachandra, Felicia Ceban, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
CNS Drugs|September 13, 2022
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic ReviewNiloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, et al.
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
Psychiatry Research|April 28, 2020
Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disordersJoshua D Rosenblat, Rodrigo B Mansur, Elisa Brietzke, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 8, 2020
Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatmentAshley N Siegel, Nelson Rodrigues, Flora Nasri, et al.
Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.
Journal of Affective Disorders|July 16, 2020
The utility of smartphone-based, ecological momentary assessment for depressive symptomsSamantha J Yim, Leanna M W Lui, Yena Lee, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
Infectious Diseases (London, England)|March 14, 2022
Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for researchFelicia Ceban, Alexia Leber, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research|June 18, 2023
Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic reviewDaniel H Cooper, Ranuk Ramachandra, Felicia Ceban, et al.
Pageof 8